Alessandra Larocca

11PUBLICATIONS
65CO-AUTHORS
Haematological tumoursMedical mycologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Feb 18, 2025
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma.

Martin F Kaiser, Pieter Sonneveld, David A Cairns

|Nov 16, 2023
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study.

Fredrik H Schjesvold, Heinz Ludwig, Maria-Victoria Mateos

|May 23, 2022
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.

Mattia D'Agostino, David A Cairns, Juan José Lahuerta

|Oct 21, 2021
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.

Alessandra Larocca, Xavier Leleu, Cyrille Touzeau

|Mar 19, 2021
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.

Alessandra Larocca, Francesca Bonello, Gianluca Gaidano

|Feb 19, 2021
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.

Evangelos Terpos, Joseph Mikhael, Roman Hajek

Pageof 2

Frequent Collaborators

5 joint publications

Mario Boccadoro

5 joint publications

María-Victoria Mateos

3 joint publications

Pieter Sonneveld

3 joint publications

Paolo Corradini